Literature DB >> 1837979

Effects of NMDA modulation in scopolamine dementia.

R W Jones1, K A Wesnes, J Kirby.   

Abstract

D-Cycloserine is a partial agonist at the strychnine-insensitive neuronal glycine receptor and positively modulates the N-methyl-D-aspartate (NMDA) excitatory amino acid receptor. NMDA receptors appear to be important in learning and memory, and D-cycloserine facilitates learning in rats. In man, central cholinergic blockade due to scopolamine administration impairs attention, information processing, and memory for new information, the latter secondary memory impairments resembling those shown in patients with Alzheimer's disease (AD). D-Cycloserine has been studied for its ability to counteract the cognitive decrements produced by scopolamine in young and elderly healthy volunteers. D-Cycloserine specifically antagonized the memory impairments produced by scopolamine. These findings provide evidence of NMDA receptor involvement in human memory and suggest a novel mechanism for alleviation of memory loss associated with aging and dementia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1837979     DOI: 10.1111/j.1749-6632.1991.tb00226.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  19 in total

1.  Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function.

Authors:  Santoshkumar Tota; Kashif Hanif; Pradeep Kumar Kamat; Abul Kalam Najmi; Chandishwar Nath
Journal:  Psychopharmacology (Berl)       Date:  2012-02-24       Impact factor: 4.530

Review 2.  Cognition enhancers in age-related cognitive decline.

Authors:  W J Riedel; J Jolles
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

3.  The scopolamine model as a pharmacodynamic marker in early drug development.

Authors:  Robert A Lenz; Jeffrey D Baker; Charles Locke; Lynne E Rueter; Eric G Mohler; Keith Wesnes; Walid Abi-Saab; Mario D Saltarelli
Journal:  Psychopharmacology (Berl)       Date:  2011-09-08       Impact factor: 4.530

4.  Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.

Authors:  Marieke Liem-Moolenaar; Peter de Boer; Maarten Timmers; Rik C Schoemaker; J G Coen van Hasselt; Stephan Schmidt; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

Review 5.  The role of the N-methyl-D-aspartate receptor in Alzheimer's disease: therapeutic potential.

Authors:  P Murali Doraiswamy
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

Review 6.  D-cycloserine for Alzheimer's disease.

Authors:  K Laake; A R Oeksengaard
Journal:  Cochrane Database Syst Rev       Date:  2002

7.  The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates.

Authors:  Jerry J Buccafusco; Alvin V Terry; Scott J Webster; Daniel Martin; Elizabeth J Hohnadel; Kristy A Bouchard; Samantha E Warner
Journal:  Psychopharmacology (Berl)       Date:  2007-07-27       Impact factor: 4.530

Review 8.  Cognitive impairment in elderly people. Predisposing factors and implications for experimental drug studies.

Authors:  J Jolles; F R Verhey; W J Riedel; P J Houx
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

Review 9.  The molecular and cellular biology of enhanced cognition.

Authors:  Yong-Seok Lee; Alcino J Silva
Journal:  Nat Rev Neurosci       Date:  2009-02       Impact factor: 34.870

10.  D-Cycloserine: Agonist turned antagonist.

Authors:  T H Lanthorn
Journal:  Amino Acids       Date:  1994-10       Impact factor: 3.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.